- Home
- RRR vs VKTX Comparison
RRR vs VKTX Comparison
Compare RRR & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RRR | VKTX |
|---|---|---|
| Founded | 1976 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.8B |
| IPO Year | 2016 | 2015 |
Fundamental Metrics
Financial Performance| Metric | RRR | VKTX |
|---|---|---|
| Price | $62.55 | $32.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 14 |
| Target Price | $62.14 | ★ $87.07 |
| AVG Volume (30 Days) | 678.4K | ★ 2.6M |
| Earning Date | 02-10-2026 | 02-04-2026 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | ★ 15.51 | N/A |
| EPS | ★ 3.14 | N/A |
| Revenue | ★ $1,995,401,000.00 | N/A |
| Revenue This Year | $4.13 | N/A |
| Revenue Next Year | $3.47 | N/A |
| P/E Ratio | $20.29 | ★ N/A |
| Revenue Growth | ★ 4.69 | N/A |
| 52 Week Low | $35.09 | $18.92 |
| 52 Week High | $64.69 | $43.15 |
Technical Indicators
Market Signals| Indicator | RRR | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.83 | 37.14 |
| Support Level | $60.43 | $31.59 |
| Resistance Level | $64.69 | $33.35 |
| Average True Range (ATR) | 1.55 | 1.49 |
| MACD | -0.16 | -0.47 |
| Stochastic Oscillator | 51.41 | 9.57 |
Price Performance
Historical ComparisonAbout RRR Red Rock Resorts Inc.
Red Rock Resorts Inc along with its subsidiary is a gaming, development and management company that develops and operates strategically-located casino and entertainment properties. Its casino properties are conveniently located throughout the Las Vegas valley and provide its customers a wide variety of entertainment and dining options. The majority of revenue is derived from Casinos.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.